877 coy et al 1982 endocrinology 110 1445 rivier et al u s pat no 4 444 759 rivier et al ep0 038 135 bauer et al u s pat no 4 395 403 vale et al gb 2009182 filed nov 30 1978 beddell et al u s pat no 4 075 191 these lhrh analogs can be provided in the form of pharmaceutically acceptable salts examples of preferred salts are those with therapeutically acceptable organic acids e g acetic lactic maleic citric malic ascorbic succinic benzoic salicylic methanesulfonic toluenesulfonic trifluoroacetic or pamoic acid as well as polymeric acids such as tannic acid or carboxymethyl cellulose and salts with inorganic acids such as the hydrohalic acids e g hydrochloric acid sulfuric acid or phosphoric acid a therapeutically effective amount of the lhrh antagonist can be administered in combination with a pharmaceutically acceptable carrier substance e g magnesium carbonate or lactose this composition can be in the form of a pill tablet capsule liquid or sustained release tablet for oral administration a liquid spray for nasal administration or a liquid for intravenous subcutaneous parenteral or intraperitoneal administration another preferred form for administration is an injectible suspension of the peptide analog with a bioerodible biocompatible polymer matrix capable of effecting sustained release of the analog other suitable forms are analog polymer implants transdermal patches transmucosal patches and compositions usable with iontophoretic techniques lhrh analogs can be tested for effectiveness in treating injured nerve tissue or preserving muscle mass according to the testing procedures described below for the lhrh analog bim 21009 bim 21009 is an antagonist of lhrh activity.